Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Transplantation ; 98(11): 1158-64, 2014 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-25269023

RESUMEN

BACKGROUND: CTLA-4 immunoglobulin fusion proteins (CTLA4-Ig) suppress immune reactions by blocking the T-cell costimulatory CD28-CD80-86 pathway and are used in clinical trials for diseases featuring exaggerated T-cell reactivity including autoimmune diseases and allograft rejection. However, because CTLA4-Ig has been suspected to interfere with T regulatory (Treg) cell homeostasis and function, recently, substantial concerns on CTLA4-Ig's potentially antitolerogenic effects have been raised. METHODS: We tested immunoregulatory CTLA4-Ig explicitly for its effect on Treg cell numbers, frequencies and function in an in vitro murine major histocompatibility complex mismatched setting using C57BL/6 bone marrow-derived dendritic cells as stimulators of allogeneic Balb/c Foxp3 T cells, which allowed for tracing Treg cells in a straightforward fashion. RESULTS: The presence of CTLA4-Ig in mixed leukocyte reactions-while dampening the global proliferative response of allostimulated Balb/c T cells-resulted in a relative increase of the frequency of thymus-derived CD4CD25Foxp3 Treg cells with intact suppressive activity. This relative increase was caused by a selective inhibitory effect of CTLA4-Ig on proliferating conventional T cells, whereas the proliferative capacity of Treg cells in cell cultures remained unaffected. Additionally, in the presence of CTLA4-Ig, the frequency of apoptosis was decreased in these cells. CONCLUSION: Our findings unequivocally demonstrate that CTLA4-Ig does not negatively affect Treg cell frequencies and function in vitro.


Asunto(s)
Inmunoconjugados/farmacología , Linfocitos T Reguladores/citología , Timo/citología , Abatacept , Animales , Apoptosis , Antígeno B7-1/metabolismo , Antígeno B7-2/metabolismo , Antígenos CD28/metabolismo , Linfocitos T CD4-Positivos/citología , Proliferación Celular , Supervivencia Celular , Femenino , Subunidad alfa del Receptor de Interleucina-2/metabolismo , Activación de Linfocitos , Prueba de Cultivo Mixto de Linfocitos , Complejo Mayor de Histocompatibilidad/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL
2.
J Neuroimmunol ; 230(1-2): 169-72, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20937531

RESUMEN

Autoantibodies to brain proteins are present in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease) patients and in the Cln3-/- mouse model of this disease, suggesting an autoimmune component to pathogenesis. Using genetic or pharmaceutical approaches to attenuate this immune response in Cln3-/- mice, we demonstrate decreased neuroinflammation, decreased deposition of immunoglobulin G in the brain and protection of vulnerable neuron populations. Moreover, immune suppression results in a significant improvement in motor performance providing for the first plausible therapeutic approach for juvenile Batten disease.


Asunto(s)
Encéfalo/efectos de los fármacos , Terapia de Inmunosupresión , Inmunosupresores/farmacología , Lipofuscinosis Ceroideas Neuronales/tratamiento farmacológico , Lipofuscinosis Ceroideas Neuronales/inmunología , Animales , Autoanticuerpos/efectos de los fármacos , Autoanticuerpos/inmunología , Western Blotting , Encéfalo/patología , Recuento de Células , Modelos Animales de Enfermedad , Inmunohistoquímica , Masculino , Glicoproteínas de Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Chaperonas Moleculares/genética , Destreza Motora/efectos de los fármacos , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/farmacología , Lipofuscinosis Ceroideas Neuronales/patología , Neuronas/efectos de los fármacos , Neuronas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA